Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Theravance Biopharma Inc (TBPH) USD0.00001

Sell:$6.03 Buy:$8.59 Change: $0.07 (0.99%)
Market closed |  Prices as at close on 24 September 2021 | Switch to live prices |
Change: $0.07 (0.99%)
Market closed |  Prices as at close on 24 September 2021 | Switch to live prices |
Change: $0.07 (0.99%)
Market closed |  Prices as at close on 24 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Theravance Biopharma, Inc. is a diversified biopharmaceutical company, which is primarily focused on the discovery, development and commercialization of organ-selective medicines. The Company develops transformational medicines to improve the lives of patients suffering from serious illnesses. The Company's research is focused in the areas of inflammation and immunology. It applies organ-selective knowledge to biologically compelling targets to discover and develop medicines, which are designed to treat underserved localized diseases and to limit systemic exposure. The Company is developing lung-selective medicines to treat respiratory disease, including YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its revefenacin is a long-acting muscarinic antagonist (LAMA). Its programs also include Nezulcitinib, Ampreloxetine (TD-9855), Izencitinib, TD-5202 and TD-8236.

Contact details

Cayman Islands
+1 (345) 6508086000

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$530.45 million
Shares in issue:
73.47 million
Cayman Islands
US dollar

Key personnel

  • Rick Winningham
    Chairman of the Board, Chief Executive Officer
  • Andrew Hindman
    Chief Financial Officer, Senior Vice President
  • Ann Brady
    President - Theravance Biopharma Ireland Limited
  • Bradford Shafer
    Executive Vice President, General Counsel, Secretary
  • Richard Graham
    Senior Vice President - Development
  • Frank Pasqualone
    Senior Vice President and Chief Commercial Operations Officer
  • Kenneth Pitzer
    Senior Vice President - Product Strategy and Commercial Planning
  • Vijay Sabesan
    Senior Vice President - Technical Operations
  • Philip Worboys
    Senior Vice President - Research and Translational Science

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.